Tuesday, April 23, 2019 - Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the Health Horizons Future Healthcare Forum in London, June 26.
Artificial intelligence (AI) has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, and help patients comply with their treatments.
At Insilico, AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for discovery, development and real world evidence collection of drugs and geroprotectors.
"The healthcare industry is just at the beginning of a revolutionary transformation and we aim to shape not just the debate, but also tangible government, industry and academic initiatives to create more innovative, but also more affordable and accessible, future healthcare that not only treats but also prevents disease," said Dr. Marek Tyl, CEO of the Innovation Forum.
"Artificial Intelligence in Healthcare has long been a concept carrying tremendous promise, with seemingly limitless potential to increase industry efficiency and improve lives on a global scale. Within biotech, AI has enabled identification of new disease mechanisms, pathways, targets and drugs to better match patients to appropriate therapies and deliver on the ideals of precision medicine. The advancements we have already achieved and the discovery work being presented by Insilico and others at the Health Horizons Future Healthcare Forum excites us about the future of healthcare," said Annastasiah Mudiwa Mhaka, Ph.D., president of the Alliance for Artificial Intelligence in Healthcare (AAIH).
"We are happy to present our latest research at the Health Horizons Future Healthcare Forum, which gathers the leading longevity leaders. The topic of machine learning implementation in drug discovery is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
Health Horizons is a high calibre, two-day conference focusing on the future of the healthcare industry. The Forum aims to deliver 1,500 attendees, more than 100 speakers, healthcare leaders and investors, to discuss the most pertinent challenges to the health ecosystems. Health Horizons is a unique conference focusing on the future of health and healthcare, which gives delegates an interdisciplinary view of the health innovation landscape. The key themes that Health Horizons aims to approach include: novel therapeutic approaches, digital health, AI and data in healthcare, cardiometabolic disease, longevity, new models for funding healthcare innovation, nanotechnology and sensing in healthcare, delivering affordable innovative medicines to patients, breakthroughs against the incurables, future of oncology and rare diseases.
###
For further information, images or interviews, please contact:
Contact: Klug Gehilfe
Website: http://insilico.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontologydemonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
Website: http://insilico.
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
No comments:
Post a Comment